2型低生物标志物稳定性和严重不受控制的喘中恶化
Arja Viinanen1,2, Juhani Aakko3, Mariann I Lassenius3
1Division of Medicine, Department of Pulmonary Diseases, Turku University Hospital, 20014 Turku, Finland.
Biomolecules
|July 29, 2023
概括
低T2喘生物标志物概况,通过血中乙氨基酸细胞计数 (BEC) 和部分呼出的氧化 (FeNO) 来确定,在大多数严重不受控制的喘患者中是稳定的. 这种稳定性对于准确的诊断和治疗策略至关重要.
科学领域:
- 肺部病理学 肺部病理学
- 过敏和免疫学 过敏和免疫学
- 生物标志物研究 生物标志物研究
背景情况:
- 严重不受控制的喘管理需要精确的患者表型.
- 低T2喘表型,以特定的生物标志物水平为特征,尚未确定,其纵向稳定性在很大程度上是未知的.
- 了解T2低生物标志物稳定性对于严重喘的有效治疗策略至关重要.
研究的目的:
- 为了研究T2低状态的稳定性,使用血液中乙酸盐计数 (BEC) 和分数呼出的氧化 (FeNO) 在患有严重不受控制的喘的患者中.
- 为了确定T2低与非T2低喘表型中的恶化率.
- 评估BEC和FeNO作为生物标志物的可靠性,以识别和监测T2低喘随时间推移.
主要方法:
- 对来自严重失控喘患者的临床数据的回顾性分析,至少有两次BEC和FeNO测量.
- 根据已确定的BEC (<150或<300细胞/μL) 和FeNO (<25ppb) 值,将患者分为低T2和非低T2组.
- 在4年的随访期间评估生物标志物状态稳定性,需要住院治疗的恶化率和药物剂量 (OCS,ICS).
主要成果:
- 18%的患者被归类为使用BEC<150细胞/μL和FeNO<25ppb的T2低,而39%的患者使用BEC<300细胞/μL和FeNO<25ppb的T2低.
- 低T2生物标志物概况在55% (T2低150) 和72% (T2低300) 的患者中表现出稳定性,随着可用的随访数据.
- 与非T2低150组 (8.4/100患者年) 相比,T2低150组 (19.7/100患者年) 的恶化率更高.
结论:
- 血中乙酸细胞计数 (BEC) 和部分呼出的氧化 (FeNO) 是识别T2低严重失控喘的有价值生物标志物.
- 低T2喘表型在很大一部分患者中表现出稳定的生物标志物概况,支持其临床实用性.
- 建议定期监测BEC和FeNO,以准确识别和管理T2低喘患者.
相关概念视频
01:24Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:19Antiasthma Drugs: Leukotriene Modifiers
361
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
361
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
307
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
307
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
346
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
346